Faculty profile

John Hilton

Back to faculty

Associate ProfessorDepartment of MedicineUniversity of Ottawa

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Latest papers

The UVA-induced single-base mutational signature of CX-5461 in human cells.
Nucleic acids research · 2026
Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.
Breast cancer research and treatment · 2026
Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer.
2026

All 58 publications

Latest funding

A Liquid-Biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-Inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
CIHR · 2022 · Co-investigator
$2,184,076

All 1 grants and awards

58 publications.

The UVA-induced single-base mutational signature of CX-5461 in human cells.

Zaikova E, Yap D, Sarvar A, Hafezi A, Tan J, Cerda V, Li K, Lai D, Gelmon K, Hilton J, Seymour L, Stirling P, Cescon DW, Aparicio S

Nucleic acids research2026

DOI: 10.1093/nar/gkag836 PMID: 42639791

Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.

Doyle C, Lohmann AE, Iqbal N, Henning JW, Kulkarni S, Califaretti N, Hilton J, Ferrario C, Bouganim N, Mates M, Guillemette S, Leite R, Caron MA, Thireau F, Machado A, Chia S

Breast cancer research and treatment2026

DOI: 10.1007/s10549-026-07934-4 PMID: 41854885

Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer.

Clemons M, Stober C, Pond GR, Conter H, Simos D, Dhesy-Thind S, Mates M, Trinkaus M, Hilton J, Savard M-F

20261 citations

DOI: 10.1056/evidoa2500202

Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation Study

Pilgram L, Yang K, Beltran-Bless A-A, Pond GR, Vandermeer L, Hilton J, Savard M-F, LeBlanc A, Shepherd L, Chen B

Journal of Medical Internet Research20261 citations

DOI: 10.2196/88665

Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy

Leblanc A, Beltran-Bless A-A, Pond GR, El Emam K, Juwara L, Clemons L, Bayani J, Pilgram L, Pharoah P, Mallon E

Breast Cancer Research and Treatment20261 citations

DOI: 10.1007/s10549-026-07909-5

A Randomized Trial Evaluating Personalized Versus Guideline-Based Well Follow-Up Strategies for Patients with Early Breast Cancer: Feasibility Outcomes

Beltran-Bless A-A, Himmelman E, Kim A, Pond GR, Fallah P, Ng T, Hilton J, Savard M-F, Larocque G, Baines K-A

Current Oncology2026

DOI: 10.3390/curroncol33040224

REaCT-5G: a randomized trial of bone pain with 5-day filgrastim vs pegfilgrastim for neutropenia in breast cancer.

Ng TL, Greenstreet P, Stober C, Nicholls S, Shamess J, Mills N, Ibrahim M, Savard MF, Rushton M, Awan A, Sehdev S, Hilton J, Song X, Fallah P, Alqahtani N, Davoudpour D, Daigle K, MacDonald F, Vandermeer L, Taljaard M, Clemons M

JNCI cancer spectrum2025

DOI: 10.1093/jncics/pkaf081 PMID: 40811630

Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers

Beltran-Bless A-A, Larocque G, Arnaout A, Caudrelier J-M, Hilton J, Alqahtani N, Vandermeer L, Pond G, Clemons M

Supportive Care in Cancer2025

DOI: 10.1007/s00520-025-09205-2

Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study.

Michel L, Jimeno A, Sukari A, Beck JT, Chiu J, Ahern E, Hilton J, Even C, Zanetta S, Mekan S, Patel J, Wu T, Dumbrava EE

Clinical cancer research : an official journal of the American Association for Cancer Research2025

DOI: 10.1158/1078-0432.ccr-24-2523 PMID: 39665770

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.

Doyle C, Lohmann AE, Iqbal N, Henning JW, Kulkarni S, Califaretti N, Hilton J, Ferrario C, Bouganim N, Mates M, Guillemette S, Leite R, Caron MA, Thireau F, Machado A, Chia S

Breast cancer research and treatment2025

DOI: 10.1007/s10549-024-07580-8 PMID: 39847203

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

John Hilton

Research

Latest papers

Latest funding

The UVA-induced single-base mutational signature of CX-5461 in human cells.

Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer.

Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation Study

Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy

A Randomized Trial Evaluating Personalized Versus Guideline-Based Well Follow-Up Strategies for Patients with Early Breast Cancer: Feasibility Outcomes

REaCT-5G: a randomized trial of bone pain with 5-day filgrastim vs pegfilgrastim for neutropenia in breast cancer.

Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers

Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study.

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy&#x2009;&#xb1;&#x2009;targeted therapy in HR&#x2009;+&#x2009;HER2-negative advanced breast cancer.

A Liquid-Biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-Inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Frequent collaborators

Mark Clemons

Gregory Pond

Brian Hutton

Dean Fergusson

Marie-France Savard

Angel Arnaout

Andrew Robinson

Jean-Michel Caudrelier

Sharon McGee

Jan-Willem Henning

Khaled El Emam

Lesley Seymour

Muriel Brackstone

Zuzana Kos

Melanie Spears

Eitan Amir

Samuel Aparicio

Christina Addison

Sebastien Hotte

Sukhbinder Dhesy-Thind

Derek Jonker

Joel Werier

Paul Wheatley-Price

Shailendra Verma

Urban Emmenegger

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.